Polo-like kinases (PLKs) are a family of closely related serine/threonine kinases responsible for regulating cell cycle processes and proliferation. While PLK1 inhibitors have led to clinical candidates for oncology, the biological function of other PLKs is relatively unknown, in part, because there is a dearth of selective tool compounds. Herein we report the parallel medicinal chemistry (PMC) and structure-assisted discovery of potent and selective PLK3 inhibitors with favorable drug-like properties. We employed computational tools to reveal subtly different pharmacophore features within homologous binding sites of PLKs. These preferences were then exploited via a PMC approach starting from in-house high-throughput screening hits, resulting in selective chemical probes that help elucidate the complexities of PLK biology. Further, by profiling compounds with a spectrum of PLK selectivities, our work demonstrates the relationship between inhibition of specific PLK isoforms and resulting toxicities.
Yap et al. (Tue,) studied this question.